KSP inhibitors have shown efficacy in a variety of cancers, including breast cancer, ovarian cancer, and non-small cell lung cancer. Clinical trials are ongoing to expand their applicability to other cancer types. The success of these trials will determine the broader potential of KSP inhibitors in oncology.
